Posted in | News | Nanomedicine

New Nanocomplex DOX/TPOR4@CB[7]4 Shows Potent Anti-Cancer Properties in Preclinical Studies

In a recent article published in Pharmaceutics, researchers introduced a self-assembled nanocomposite designed for enhanced synergistic photodynamic therapy and chemotherapy in neuroblastoma.

Neuroblastoma is a challenging cancer to treat, necessitating innovative approaches for improved therapeutic outcomes. The nanocomposite aims to combine the benefits of photodynamic therapy and chemotherapy to enhance anti-tumor efficacy.

??????????????Study: Self-Assembled Nanocomposite DOX/TPOR4@CB[7]4 for Enhanced Synergistic Photodynamic Therapy and Chemotherapy in Neuroblastoma. Image Credit: tilialucida/Shutterstock.com​​​​​​​Study: Self-Assembled Nanocomposite DOX/TPOR4@CB[7]4 for Enhanced Synergistic Photodynamic Therapy and Chemotherapy in Neuroblastoma. Image Credit: tilialucida/Shutterstock.com

Background

Developing novel therapeutic strategies for neuroblastoma is crucial due to its resistance to conventional treatments. The combination of photodynamic therapy and chemotherapy has shown promise in enhancing treatment efficacy by targeting cancer cells through different mechanisms.

The drug Doxorubicin (DOX) exhibits wide-ranging antitumor efficacy and acts as a radiosensitizer in treating neuroblastoma.

Nanocomposites offer a unique opportunity to deliver multiple therapeutic agents simultaneously, potentially improving treatment outcomes.

The Current Study

The DOX/TPOR4@CB[7]4 nanocomposite was synthesized via self-assembly. Initially, DOX, TPOR4, and CB[7] were dissolved in a suitable solvent under controlled conditions to facilitate the formation of the nanocomposite.

The specific molar ratios of the components were optimized to ensure efficient self-assembly and stability of the final product. The self-assembly process was carefully monitored to track the formation of the nanocomposite and confirm the successful encapsulation of TPOR4 within the CB[7] cavity.

Various analytical techniques were employed to characterize the physicochemical properties of the DOX/TPOR4@CB[7]4 nanocomposite. Spectroscopic methods such as UV-Vis spectroscopy and fluorescence spectroscopy were used to assess the optical properties of the nanocomposite.

Dynamic light scattering (DLS) and zeta potential measurements were conducted to determine the nanocomposite's size distribution and surface charge.

Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) were utilized to visualize the morphology and structure of the nanocomposite at the nanoscale level.

The ability of the DOX/TPOR4@CB[7]4 nanocomposite to generate reactive oxygen species (ROS) was evaluated using a fluorescence-based assay.

ROS production is a crucial aspect of photodynamic therapy, as it plays a key role in inducing cytotoxic effects on cancer cells. The nanocomposite was exposed to specific light wavelengths to trigger ROS generation, and the resulting fluorescence intensity was measured to quantify the ROS production capacity of the nanocomposite.

The impact of photodynamic therapy on SH-SY5Y neuroblastoma cells was assessed using the MTT assay to evaluate cell viability post-treatment. Flow cytometry analysis was employed to detect apoptosis rates in the treated cells, providing insights into the cytotoxic effects of the nanocomposite.

Confocal laser scanning microscopy was utilized to visualize the intracellular distribution of the DOX/TPOR4@CB[7]4 nanocomposite within the SH-SY5Y cells, offering valuable information on cellular uptake and localization.

Results and Discussion

The physicochemical properties of the DOX/TPOR4@CB[7]4 nanocomposite were thoroughly characterized to understand its structural integrity and stability. UV-Vis and fluorescence spectroscopy revealed distinct optical features of the nanocomposite, indicating successful encapsulation of TPOR4 within the CB[7] cavity.

Dynamic light scattering (DLS) and zeta potential measurements demonstrated a uniform size distribution and stable surface charge of the nanocomposite, essential for efficient drug delivery and cellular uptake. SEM and TEM imaging confirmed the nanoscale morphology of the nanocomposite, highlighting its potential for targeted drug delivery applications.

The ability of the DOX/TPOR4@CB[7]4 nanocomposite to generate reactive oxygen species (ROS) was critical to its photodynamic therapy efficacy.

The fluorescence-based assay indicated a significant increase in ROS production upon light exposure, suggesting the nanocomposite's potential to induce cytotoxic effects on cancer cells through ROS-mediated pathways. This enhanced ROS generation capability is a key factor in the nanocomposite's anti-tumor activity and underscores its promise for synergistic photodynamic therapy.

In vitro studies on SH-SY5Y neuroblastoma cells demonstrated the potent cytotoxic effects of the DOX/TPOR4@CB[7]4 nanocomposite. The MTT assay revealed a marked decrease in cell viability following treatment, indicating the nanocomposite's efficacy in inhibiting cancer cell proliferation.

Flow cytometry analysis further confirmed elevated apoptosis rates in the treated cells, highlighting the nanocomposite's ability to induce programmed cell death in neuroblastoma cells.

Confocal laser scanning microscopy provided visual evidence of the intracellular distribution of the nanocomposite, showing efficient uptake and localization within the cancer cells, which is crucial for targeted drug delivery and therapeutic efficacy.

The in vivo evaluation of the DOX/TPOR4@CB[7]4 nanocomposite in nude mice bearing SH-SY5Y tumors demonstrated promising results. Fluorescence imaging revealed enhanced tumor accumulation and prolonged retention of the nanocomposite, indicating its superior targeting ability and sustained drug release kinetics.

Tumor growth inhibition studies showed significant reductions in tumor volume and weight in the nanocomposite-treated group compared to controls, underscoring its potent anti-cancer effects.

Histopathological analysis of major organs demonstrated minimal toxicity, suggesting the nanocomposite's biocompatibility and safety profile for in vivo applications.

Conclusion

The study concludes that the self-assembled nanocomposite DOX/TPOR4@CB[7]4 holds promise for enhanced synergistic photodynamic therapy and chemotherapy in neuroblastoma.

The combination of DOX, TPOR4, and CB[7] in the nanocomposite demonstrated superior anti-tumor effects both in vitro and in vivo. The findings suggest that this nanocomposite could be a valuable therapeutic approach for neuroblastoma treatment, offering improved efficacy with minimal toxicity.

Journal Reference

Dr. Noopur Jain

Written by

Dr. Noopur Jain

Dr. Noopur Jain is an accomplished Scientific Writer based in the city of New Delhi, India. With a Ph.D. in Materials Science, she brings a depth of knowledge and experience in electron microscopy, catalysis, and soft materials. Her scientific publishing record is a testament to her dedication and expertise in the field. Additionally, she has hands-on experience in the field of chemical formulations, microscopy technique development and statistical analysis.    

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Jain, Noopur. (2024, July 02). New Nanocomplex DOX/TPOR4@CB[7]4 Shows Potent Anti-Cancer Properties in Preclinical Studies. AZoNano. Retrieved on July 14, 2024 from https://www.azonano.com/news.aspx?newsID=40948.

  • MLA

    Jain, Noopur. "New Nanocomplex DOX/TPOR4@CB[7]4 Shows Potent Anti-Cancer Properties in Preclinical Studies". AZoNano. 14 July 2024. <https://www.azonano.com/news.aspx?newsID=40948>.

  • Chicago

    Jain, Noopur. "New Nanocomplex DOX/TPOR4@CB[7]4 Shows Potent Anti-Cancer Properties in Preclinical Studies". AZoNano. https://www.azonano.com/news.aspx?newsID=40948. (accessed July 14, 2024).

  • Harvard

    Jain, Noopur. 2024. New Nanocomplex DOX/TPOR4@CB[7]4 Shows Potent Anti-Cancer Properties in Preclinical Studies. AZoNano, viewed 14 July 2024, https://www.azonano.com/news.aspx?newsID=40948.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.